Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions.
1. 1 Introduction - p. 225 2. 2 Centrally acting antiobesity drugs - p. 226 3. 3 Gastrointestinal and pancreatic peptides that regulate food intake - p. 231 4. 4 Peripheral target organs - p. 236 5. 5 Peripheral modulators of the efficacy of digestion, metabolism, and lipogenesis - p. 237 6. 6 Alternative types of drugs - p. 238 7. 7 New drugs in combinations - p. 241 8. 8 Combination therapy with GLP-1 receptor agonist plus SGLT2 inhibitor - p. 246 9. 9 Combination therapy of GLP-1 receptor agonist plus amylin analogue - p. 247 10. 10 Combination therapy of GLP-1 receptor agonist plus cholecystokinin (CCK) - p. 247 11. 11 Combination therapy of GLP-1 receptor agonists plus PYY analogs - p. 247 12. 12 Discussion - p. 248 13. Chapter 14. Adipose tissue: A target for prevention and treatment of metabolic diseases - p. 259 14. Part IV. Metabolic syndrome - p. 271 15. Chapter 15. Metabolic syndrome: Pharmacological strategies and challenges - p. 273 16. Chapter 16. Pharmacological targets in metabolic syndrome related dyslipidemia - p. 289 17. Chapter 17. Plant molecules and metabolic syndrome: Therapeutic opportunities - p. 309 18. Part V. Natural molecules and metabolic diseases and disorders - p. 319 19. Chapter 18. Polyphenols and obesity: Molecular targets and therapeutic potential - p. 321 20. Chapter 19. Plant molecules: Prevention and management of diabetes mellitus - p. 335 21. Chapter 20. Molecular targets in dyslipidemia: Therapeutic potential of plant molecules - p. 353 22. Chapter 21. Polyphenols and the control of immunometabolism as a pharmacological target - p. 365 23. Part VI. Microbiota and metabolic diseases and disorders - p. 383 24. Chapter 22. Microbiota, metabolic disorders, and pharmacological opportunities - p. 385 25. Chapter 23. Gut microbiota as a pharmacological target in cardiovascular diseases - p. 403 26. Chapter 24. Plant molecules in obesity and the gut microbiota - p. 417 27. Chapter 25. Microbiota and fatty liver disease: Potential candidate for therapeutic intervention - p. 435 28. Part VII. Nutrition and food interactions - p. 453 29. Chapter 26. Nutrition and drug interactions in metabolic diseases - p. 455 30. Index - p. 477
Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities is a complete reference on possible drug development targets to be leveraged in therapeutic developments. Covering both signaling pathways and specific proteins, the book presents ways to modulate the molecular and cellular alterations observed in metabolic diseases and disorders through the application of new or classical drugs. The comprehensive coverage starts by providing an overview of metabolic diseases and disorders, biological alterations, and pharmacological targets. This section covers targets at both molecular, and subcellular and cellular levels. The next section in the book is focused on pharmaceutical targeting of organs, including a dedicated chapter to the gut-brain axis. Next comes a thorough review of the current advances in metabolic syndrome research. Section VI is focused on inborn errors of metabolism and is followed by a section devoted to natural molecules and their pharmacological potential to treat these conditions. The Editor introduces next a whole section dedicated to the role of the microbiota in metabolic diseases therapeutics. The following sections cover the impact of aging, nanotechnology, the environment, and finally diagnostic techniques in metabolic diseases and disorders. Pharmacological Targets in Metabolic Diseases: Challenges and Opportunities meet the needs of pharmacology researchers looking for a comprehensive and authoritative source of information on possible therapeutic targets to treat these conditions. Research physicians, nutritionists, pharmacists, and biologists can benefit from the detailed information provided at the different levels of targets identified to treat metabolic diseases and conditions.
1. 1 Introduction - p. 225 2. 2 Centrally acting antiobesity drugs - p. 226 3. 3 Gastrointestinal and pancreatic peptides that regulate food intake - p. 231 4. 4 Peripheral target organs - p. 236 5. 5 Peripheral modulators of the efficacy of digestion, metabolism, and lipogenesis - p. 237 6. 6 Alternative types of drugs - p. 238 7. 7 New drugs in combinations - p. 241 8. 8 Combination therapy with GLP-1 receptor agonist plus SGLT2 inhibitor - p. 246 9. 9 Combination therapy of GLP-1 receptor agonist plus amylin analogue - p. 247 10. 10 Combination therapy of GLP-1 receptor agonist plus cholecystokinin (CCK) - p. 247 11. 11 Combination therapy of GLP-1 receptor agonists plus PYY analogs - p. 247 12. 12 Discussion - p. 248 13. Chapter 14. Adipose tissue: A target for prevention and treatment of metabolic diseases - p. 259 14. Part IV. Metabolic syndrome - p. 271 15. Chapter 15. Metabolic syndrome: Pharmacological strategies and challenges - p. 273 16. Chapter 16. Pharmacological targets in metabolic syndrome related dyslipidemia - p. 289 17. Chapter 17. Plant molecules and metabolic syndrome: Therapeutic opportunities - p. 309 18. Part V. Natural molecules and metabolic diseases and disorders - p. 319 19. Chapter 18. Polyphenols and obesity: Molecular targets and therapeutic potential - p. 321 20. Chapter 19. Plant molecules: Prevention and management of diabetes mellitus - p. 335 21. Chapter 20. Molecular targets in dyslipidemia: Therapeutic potential of plant molecules - p. 353 22. Chapter 21. Polyphenols and the control of immunometabolism as a pharmacological target - p. 365 23. Part VI. Microbiota and metabolic diseases and disorders - p. 383 24. Chapter 22. Microbiota, metabolic disorders, and pharmacological opportunities - p. 385 25. Chapter 23. Gut microbiota as a pharmacological target in cardiovascular diseases - p. 403 26. Chapter 24. Plant molecules in obesity and the gut microbiota - p. 417 27. Chapter 25. Microbiota and fatty liver disease: Potential candidate for therapeutic intervention - p. 435 28. Part VII. Nutrition and food interactions - p. 453 29. Chapter 26. Nutrition and drug interactions in metabolic diseases - p. 455 30. Index - p. 477
